Viatris Inc. shares fall 1.13% intraday as Theravance Biopharma completes enrollment in pivotal Phase 3 trial.

Viatris Inc. declined 1.13% in intraday trading. Theravance Biopharma, a company that has a partnership with Viatris, completed enrollment in the pivotal Phase 3 trial for ampreloxetine, a potential treatment for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The drug has Orphan Drug Designation in the U.S., highlighting the unmet need in this area. Topline results are anticipated in Q1 2026, with plans for an expedited NDA submission if successful.